Context Therapeutics (CNTX) Accumulated Expenses (2020 - 2026)

Context Therapeutics has disclosed Accumulated Expenses across 7 years of filings, most recently posting $3.9 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3.9 million, up 396.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 million (up 396.15% YoY), and the FY2025 annual result was $5.4 million, up 352.1% from the prior year.
• Accumulated Expenses came in at $3.9 million for Q1 2026 at Context Therapeutics, down from $5.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.4 million in Q4 2025 to a low of $563058.0 in Q1 2024.
• The 5-year median for Accumulated Expenses is $2.0 million (2022), against an average of $2.1 million.
• Across the five-year window, Accumulated Expenses slumped 71.73% in 2024 and jumped 396.15% in 2026, its largest moves.
• Context Therapeutics' Accumulated Expenses stood at $2.2 million in 2022, then slipped by 18.39% to $1.8 million in 2023, then sank by 34.27% to $1.2 million in 2024, then jumped by 352.1% to $5.4 million in 2025, then declined by 27.28% to $3.9 million in 2026.
• The last three Accumulated Expenses figures came in at $3.9 million (Q1 2026), $5.4 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.